Valvular heart disease and cardiomyopathy: reappraisal of their interplay.
Journal
Nature reviews. Cardiology
ISSN: 1759-5010
Titre abrégé: Nat Rev Cardiol
Pays: England
ID NLM: 101500075
Informations de publication
Date de publication:
Jan 2024
Jan 2024
Historique:
accepted:
03
07
2023
pubmed:
11
8
2023
medline:
11
8
2023
entrez:
10
8
2023
Statut:
ppublish
Résumé
Cardiomyopathies and valvular heart diseases are typically considered distinct diagnostic categories with dedicated guidelines for their management. However, the interplay between these conditions is increasingly being recognized and they frequently coexist, as in the paradigmatic examples of dilated cardiomyopathy and hypertrophic cardiomyopathy, which are often complicated by the occurrence of mitral regurgitation. Moreover, cardiomyopathies and valvular heart diseases can have a shared aetiology because several genetic or acquired diseases can affect both the cardiac valves and the myocardium. In addition, the association between cardiomyopathies and valvular heart diseases has important prognostic and therapeutic implications. Therefore, a better understanding of their shared pathophysiological mechanisms, as well as of the prevalence and predisposing factors to their association, might lead to a different approach in the risk stratification and management of these diseases. In this Review, we discuss the different scenarios in which valvular heart diseases and cardiomyopathies coexist, highlighting the need for an improved classification and clustering of these diseases with potential repercussions in the clinical management and, particularly, personalized therapeutic approaches.
Identifiants
pubmed: 37563454
doi: 10.1038/s41569-023-00911-0
pii: 10.1038/s41569-023-00911-0
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
37-50Informations de copyright
© 2023. Springer Nature Limited.
Références
Vahanian, A. et al. 2021 ESC/EACTS guidelines for the management of valvular heart disease. Eur. Heart J. 43, 561–632 (2022).
pubmed: 34453165
doi: 10.1093/eurheartj/ehab395
Elliott, P. et al. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology working group on myocardial and pericardial diseases. Eur. Heart J. 29, 270–276 (2008).
pubmed: 17916581
doi: 10.1093/eurheartj/ehm342
McKenna, W. J., Maron, B. J. & Thiene, G. Classification, epidemiology, and global burden of cardiomyopathies. Circ. Res. 121, 722–730 (2017).
pubmed: 28912179
doi: 10.1161/CIRCRESAHA.117.309711
Lancellotti, P., Zamorano, J. L. & Vannan, M. A. Imaging challenges in secondary mitral regurgitation: unsolved issues and perspectives. Circ. Cardiovasc. Imaging 7, 735–746 (2014).
pubmed: 25027455
doi: 10.1161/CIRCIMAGING.114.000992
Wigle, E. D. Cardiomyopathy: the diagnosis of hypertrophic cardiomyopathy. Heart 86, 709–714 (2001).
pubmed: 11711479
pmcid: 1730029
doi: 10.1136/heart.86.6.709
Milleron, O. et al. Eclipsed mitral regurgitation: an unusual cause of acute heart failure. Eur. Heart J. Cardiovasc. Imaging 18, 1163–1169 (2017).
pubmed: 27625364
doi: 10.1093/ehjci/jew192
Agricola, E. et al. Non-ischemic dilated cardiopathy: prognostic value of functional mitral regurgitation. Int. J. Cardiol. 146, 426–428 (2010).
pubmed: 21094544
doi: 10.1016/j.ijcard.2010.10.096
He, S., Fontaine, A. A., Schwammenthal, E., Yoganathan, A. P. & Levine, R. A. Integrated mechanism for functional mitral regurgitation: leaflet restriction versus coapting force: in vitro studies. Circulation 96, 1826–1834 (1997).
pubmed: 9323068
doi: 10.1161/01.CIR.96.6.1826
Levack, M. M. et al. Three-dimensional echocardiographic analysis of mitral annular dynamics: implication for annuloplasty selection. Circulation 126, S183–S188 (2012).
pubmed: 22965981
pmcid: 3458517
doi: 10.1161/CIRCULATIONAHA.111.084483
Rossi, A. et al. Independent prognostic value of functional mitral regurgitation in patients with heart failure. A quantitative analysis of 1256 patients with ischaemic and non-ischaemic dilated cardiomyopathy. Heart 97, 1675–1680 (2011).
pubmed: 21807656
doi: 10.1136/hrt.2011.225789
Mack, M. & Grayburn, P. Guideline-directed medical therapy for secondary mitral regurgitation: more questions than answers! JACC Heart Fail. 5, 660–662 (2017).
pubmed: 28859755
doi: 10.1016/j.jchf.2017.07.007
El Sabbagh, A., Reddy, Y. N. V. & Nishimura, R. A. Mitral valve regurgitation in the contemporary era: insights into diagnosis, management, and future directions. JACC Cardiovasc. Imaging 11, 628–643 (2018).
pubmed: 29622181
doi: 10.1016/j.jcmg.2018.01.009
Kajimoto, K., Minami, Y., Otsubo, S. & Sato, N. Ischemic or nonischemic functional mitral regurgitation and outcomes in patients with acute decompensated heart failure with preserved or reduced ejection fraction. Am. J. Cardiol. 120, 809–816 (2017).
pubmed: 28705383
doi: 10.1016/j.amjcard.2017.05.051
Trichon, B. H., Felker, G. M., Shaw, L. K., Cabell, C. H. & O’Connor, C. M. Relation of frequency and severity of mitral regurgitation to survival among patients with left ventricular systolic dysfunction and heart failure. Am. J. Cardiol. 91, 538–543 (2003).
pubmed: 12615256
doi: 10.1016/S0002-9149(02)03301-5
Goliasch, G. et al. Refining the prognostic impact of functional mitral regurgitation in chronic heart failure. Eur. Heart J. 39, 39–46 (2018).
pubmed: 29020337
doi: 10.1093/eurheartj/ehx402
Seneviratne, B., Moore, G. A. & West, P. D. Effect of captopril on functional mitral regurgitation in dilated heart failure: a randomised double blind placebo controlled trial. Br. Heart J. 72, 63–68 (1994).
pubmed: 8068472
pmcid: 1025427
doi: 10.1136/hrt.72.1.63
Nasser, R. et al. Evolution of functional mitral regurgitation and prognosis in medically managed heart failure patients with reduced ejection fraction. JACC Heart Fail. 5, 652–659 (2017).
pubmed: 28859754
doi: 10.1016/j.jchf.2017.06.015
Pagnesi, M. et al. Clinical impact of changes in mitral regurgitation severity after medical therapy optimization in heart failure. Clin. Res. Cardiol. 111, 912–923 (2022).
pubmed: 35294624
pmcid: 9334376
doi: 10.1007/s00392-022-01991-7
Kang, D. H. et al. Angiotensin receptor neprilysin inhibitor for functional mitral regurgitation. Circulation 139, 1354–1365 (2019).
pubmed: 30586756
doi: 10.1161/CIRCULATIONAHA.118.037077
Cabrera-Bueno, F. et al. Persistence of secondary mitral regurgitation and response to cardiac resynchronization therapy. Eur. J. Echocardiogr. 11, 131–137 (2010).
pubmed: 19939817
doi: 10.1093/ejechocard/jep184
Verhaert, D. et al. Impact of mitral regurgitation on reverse remodeling and outcome in patients undergoing cardiac resynchronization therapy. Circ. Cardiovasc. Imaging 5, 21–26 (2012).
pubmed: 22047983
doi: 10.1161/CIRCIMAGING.111.966580
Van Bommel, R. J. et al. Cardiac resynchronization therapy as a therapeutic option in patients with moderate–severe functional mitral regurgitation and high operative risk. Circulation 124, 912–919 (2011).
pubmed: 21810666
doi: 10.1161/CIRCULATIONAHA.110.009803
Spartera, M. et al. Role of cardiac dyssynchrony and resynchronization therapy in functional mitral regurgitation. Eur. Heart J. Cardiovasc. Imaging 17, 471–480 (2016).
pubmed: 26837899
doi: 10.1093/ehjci/jev352
Acker, M. A. et al. Mitral-valve repair versus replacement for severe ischemic mitral regurgitation. N. Engl. J. Med. 370, 23–32 (2014).
pubmed: 24245543
doi: 10.1056/NEJMoa1312808
Smith, P. K. et al. Cardiothoracic Surgical Trials Network Investigators. Surgical treatment of moderate ischemic mitral regurgitation. N. Engl. J. Med. 371, 2178–2188 (2014).
pubmed: 25405390
pmcid: 4303577
doi: 10.1056/NEJMoa1410490
Obadia, J. F. et al. Percutaneous repair or medical treatment for secondary mitral regurgitation. N. Engl. J. Med. 379, 2297–2306 (2018).
pubmed: 30145927
doi: 10.1056/NEJMoa1805374
Stone, G. W. et al. Transcatheter mitral-valve repair in patients with heart failure. N. Engl. J. Med. 379, 2307–2318 (2018).
pubmed: 30280640
doi: 10.1056/NEJMoa1806640
Chiarito, M. et al. Edge-to-edge percutaneous mitral repair for functional ischaemic and non-ischaemic mitral regurgitation: a systematic review and meta-analysis. Esc. Heart Fail. 9, 3177–3187 (2022).
pubmed: 35770326
pmcid: 9715840
doi: 10.1002/ehf2.13772
Grayburn, P. A., Sannino, A. & Packer, M. Proportionate and disproportionate functional mitral regurgitation: a new conceptual framework that reconciles the results of the MITRA-FR and COAPT trials. JACC Cardiovasc. Imaging 12, 353–362 (2019).
pubmed: 30553663
doi: 10.1016/j.jcmg.2018.11.006
Lindenfeld, J. et al. Association of effective regurgitation orifice area to left ventricular end-diastolic volume ratio with transcatheter mitral valve repair outcomes: a secondary analysis of the COAPT trial. JAMA Cardiol. 6, 427–443 (2021).
pubmed: 33533873
doi: 10.1001/jamacardio.2020.7200
Ooms, J. F. et al. Transcatheter edge-to-edge repair in proportionate versus disproportionate functional mitral regurgitation. J. Am. Soc. Echocardiogr. 35, 105–115e8 (2022).
pubmed: 34389469
doi: 10.1016/j.echo.2021.08.002
Orban, M. et al. Impact of proportionality of secondary mitral regurgitation on outcome after transcatheter mitral valve repair. JACC Cardiovasc. Imaging 14, 715–725 (2021).
pubmed: 32861652
doi: 10.1016/j.jcmg.2020.05.042
Adamo, M. et al. COAPT-like profile predicts long-term outcomes in patients with secondary mitral regurgitation undergoing mitraclip implantation. JACC Cardiovasc. Interv. 14, 15–25 (2021).
pubmed: 33309313
doi: 10.1016/j.jcin.2020.09.050
Brener, M. I. et al. Right ventricular–pulmonary arterial coupling in patients with HF secondary MR: analysis from the COAPT trial. JACC Cardiovasc. Interv. 14, 2231–2242 (2021).
pubmed: 34674862
doi: 10.1016/j.jcin.2021.07.047
Otto, C. M. et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 143, e72–e227 (2021).
pubmed: 33332150
Rose, E. A. et al. Long-term use of a left ventricular assist device for end-stage heart failure. N. Engl. J. Med. 345, 1435–1443 (2001).
pubmed: 11794191
doi: 10.1056/NEJMoa012175
Maron, B. J. et al. Diagnosis and evaluation of hypertrophic cardiomyopathy: JACC state-of-the-art review. J. Am. Coll. Cardiol. 79, 372–389 (2022).
pubmed: 35086660
doi: 10.1016/j.jacc.2021.12.002
Ommen, S. R. et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: executive summary: a report of The American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J. Am. Coll. Cardiol. 76, 3022–3055 (2020).
pubmed: 33229115
doi: 10.1016/j.jacc.2020.08.044
Woo, A. & Jedrzkiewicz, S. The mitral valve in hypertrophic cardiomyopathy: it’s a long story. Circulation 124, 9–12 (2011).
pubmed: 21730319
doi: 10.1161/CIRCULATIONAHA.111.035568
Maron, M. S. et al. Mitral valve abnormalities identified by cardiovascular magnetic resonance represent a primary phenotypic expression of hypertrophic cardiomyopathy. Circulation 124, 40–47 (2011).
pubmed: 21670234
doi: 10.1161/CIRCULATIONAHA.110.985812
Levine, R. A. et al. Papillary muscle displacement causes systolic anterior motion of the mitral valve. Experimental validation and insights into the mechanism of subaortic obstruction. Circulation 91, 1189–1195 (1995).
pubmed: 7850958
doi: 10.1161/01.CIR.91.4.1189
Klues, H. G., Roberts, W. C. & Maron, B. J. Anomalous insertion of papillary muscle directly into anterior mitral leaflet in hypertrophic cardiomyopathy. Significance in producing left ventricular outflow obstruction. Circulation 84, 1188–1197 (1991).
pubmed: 1884449
doi: 10.1161/01.CIR.84.3.1188
Groarke, J. D. et al. Intrinsic mitral valve alterations in hypertrophic cardiomyopathy sarcomere mutation carriers. Eur. Heart J. Cardiovasc. Imaging 19, 1109–1116 (2018).
pubmed: 30052928
pmcid: 6148328
doi: 10.1093/ehjci/jey095
Ferrazzi, P. et al. Congenital muscular mitral-aortic discontinuity identified in patients with obstructive hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 76, 2238–2247 (2020).
pubmed: 33153584
doi: 10.1016/j.jacc.2020.09.534
Olivotto, I., Cecchi, F., Poggesi, C. & Yacoub, M. H. Developmental origins of hypertrophic cardiomyopathy phenotypes: a unifying hypothesis. Nat. Rev. Cardiol. 6, 317–321 (2009).
pubmed: 19352336
doi: 10.1038/nrcardio.2009.9
Djenoune, L., Berg, K., Brueckner, M. & Yuan, S. A change of heart: new roles for cilia in cardiac development and disease. Nat. Rev. Cardiol. 19, 211–227 (2022).
pubmed: 34862511
doi: 10.1038/s41569-021-00635-z
Wigle, E. D., Adelman, A., Auger, P. & Marquis, Y. Mitral regurgitation in muscular subaortic stenosis. Am. J. Cardiol. 24, 698–706 (1969).
pubmed: 4310527
doi: 10.1016/0002-9149(69)90457-3
Rowin, E. J., Maron, B. J., Olivotto, I. & Maron, M. S. Role of exercise testing in hypertrophic cardiomyopathy. JACC Cardiovasc. Imaging 10, 1374–1386 (2017).
pubmed: 29122139
doi: 10.1016/j.jcmg.2017.07.016
Maron, M. S. et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N. Engl. J. Med. 348, 295–303 (2003).
pubmed: 12540642
doi: 10.1056/NEJMoa021332
Maron, B. J., Rowin, E. J., Udelson, J. E. & Maron, M. S. Clinical spectrum and management of heart failure in hypertrophic cardiomyopathy. JACC Heart Fail. 6, 353–363 (2018).
pubmed: 29655822
doi: 10.1016/j.jchf.2017.09.011
Elliott, P. M. et al. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). Eur. Heart J. 35, 2733–2779 (2014).
pubmed: 25173338
doi: 10.1093/eurheartj/ehu284
Maron, B. J. et al. Left atrial remodeling in hypertrophic cardiomyopathy and susceptibility markers for atrial fibrillation identified by cardiovascular magnetic resonance. Am. J. Cardiol. 113, 1394–1400 (2014).
pubmed: 24589281
doi: 10.1016/j.amjcard.2013.12.045
Feneon, D. et al. Impact of exercise-induced mitral regurgitation on hypertrophic cardiomyopathy outcomes. Eur. Heart J. Cardiovasc. Imaging 17, 1110–1117 (2016).
pubmed: 26476399
doi: 10.1093/ehjci/jev242
Olivotto, I., Cecchi, F., Poggesi, C. & Yacoub, M. H. Patterns of disease progression in hypertrophic cardiomyopathy: an individualized approach to clinical staging. Circ. Heart Fail. 5, 535–546 (2012).
pubmed: 22811549
doi: 10.1161/CIRCHEARTFAILURE.112.967026
Hong, J. H. et al. Mitral regurgitation in patients with hypertrophic obstructive cardiomyopathy: implications for concomitant valve procedures. J. Am. Coll. Cardiol. 68, 1497–1504 (2016).
pubmed: 27687190
doi: 10.1016/j.jacc.2016.07.735
Iacovoni, A. et al. A contemporary European experience with surgical septal myectomy in hypertrophic cardiomyopathy. Eur. Heart J. 33, 2080–2087 (2012).
pubmed: 22522842
pmcid: 3418509
doi: 10.1093/eurheartj/ehs064
Pelliccia, F. et al. Multidisciplinary evaluation and management of obstructive hypertrophic cardiomyopathy in 2020: towards the HCM Heart Team. Int. J. Cardiol. 304, 86–92 (2020).
pubmed: 31983465
doi: 10.1016/j.ijcard.2020.01.021
Maron, B. J. et al. The case for surgery in obstructive hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 44, 2044–2053 (2004).
pubmed: 15542290
doi: 10.1016/j.jacc.2004.04.063
Ferrazzi, P. et al. Transaortic chordal cutting: mitral valve repair for obstructive hypertrophic cardiomyopathy with mild septal hypertrophy. J. Am. Coll. Cardiol. 66, 1687–1696 (2015).
pubmed: 26449139
doi: 10.1016/j.jacc.2015.07.069
Morcos, M., Strobel, A., Messenger, J. & Gill, E. Treatment of severe left ventricular outflow tract obstruction and mitral regurgitation with alcohol septal ablation. CASE 6, 387–391 (2022).
pubmed: 36247378
pmcid: 9556931
doi: 10.1016/j.case.2022.06.006
Nielsen, C. D., Fernandes, V. & Spencer, W. H. III Alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Am. Heart Hosp. J. 1, 83–90 (2003).
pubmed: 15785181
doi: 10.1111/j.1541-9215.2003.02091.x
Krajcer, Z., Leachman, R. D., Cooley, D. A. & Coronado, R. Septal myotomy-myomectomy versus mitral valve replacement in hypertrophic cardiomyopathy. Ten-year follow-up in 185 patients. Circulation 80, I57–I64 (1989).
pubmed: 2766539
Sherrid, M. V., Balaram, S., Kim, B., Axel, L. & Swistel, D. G. The mitral valve in obstructive hypertrophic cardiomyopathy: a test in context. J. Am. Coll. Cardiol. 67, 1846–1858 (2016).
pubmed: 27081025
doi: 10.1016/j.jacc.2016.01.071
Afanasyev, A. V. et al. Edge-to-Edge repair versus secondary cord cutting during septal myectomy in patients with hypertrophic obstructive cardiomyopathy: a pilot randomised study. Heart Lung Circ. 30, 438–445 (2021).
pubmed: 32718898
doi: 10.1016/j.hlc.2020.05.106
Thomas, F., Rader, F. & Siegel, R. J. The use of mitraclip for symptomatic patients with hypertrophic obstructive cardiomyopathy. Cardiology 137, 58–61 (2017).
pubmed: 28095388
doi: 10.1159/000454800
van der Lee, C., Kofflard, M. J. & van Herwerden, L. A. Sustained improvement after combined anterior mitral leaflet extension and myectomy in hypertrophic obstructive cardiomyopathy. Circulation 108, 2088–2092 (2003).
pubmed: 14517170
doi: 10.1161/01.CIR.0000092912.57140.14
Rankin, J. S. et al. A new mitral valve repair strategy for hypertrophic obstructive cardiomyopathy. J. Heart Valve Dis. 17, 642–647 (2008).
pubmed: 19137796
Delmo Walter, E. M., Siniawski, H. & Hetzer, R. Sustained improvement after combined anterior mitral valve leaflet retention plasty and septal myectomy in preventing systolic anterior motion in hypertrophic obstructive cardiomyopathy in children. Eur. J. Cardiothorac. Surg. 36, 546–552 (2009).
pubmed: 19464922
doi: 10.1016/j.ejcts.2009.03.049
Nasseri, B. A. et al. Combined anterior mitral valve leaflet retention plasty and septal myectomy in patients with hypertrophic obstructive cardiomyopathy. Eur. J. Cardiothorac. Surg. 40, 1515–1520 (2011).
pubmed: 21570861
Nistri, S. et al. β-Blockers for prevention of exercise-induced left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy. Am. J. Cardiol. 110, 715–719 (2012).
pubmed: 22633205
doi: 10.1016/j.amjcard.2012.04.051
Cohen, L. S. & Braunwald, E. Amelioration of angina pectoris in idiopathic hypertrophic subaortic stenosis with beta-adrenergic blockade. Circulation 35, 847–851 (1967).
pubmed: 6067064
doi: 10.1161/01.CIR.35.5.847
Dybro, A. M. et al. Randomized trial of metoprolol in patients with obstructive hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 78, 2505–2517 (2021).
pubmed: 34915981
doi: 10.1016/j.jacc.2021.07.065
Maron, B. J. Clinical course and management of hypertrophic cardiomyopathy. N. Engl. J. Med. 379, 655–668 (2018).
pubmed: 30110588
doi: 10.1056/NEJMra1710575
Olivotto, I. et al. EXPLORER-HCM_Study Investigators. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 396, 759–769 (2020).
pubmed: 32871100
doi: 10.1016/S0140-6736(20)31792-X
Maron, M. S. & Ommen, S. R. Exploring new and old therapies for obstructive hypertrophic cardiomyopathy: mavacamten in perspective. Circulation 143, 1181–1183 (2021).
pubmed: 33750209
doi: 10.1161/CIRCULATIONAHA.120.051330
Schönbeck, M. H. et al. Long-term follow-up in hypertrophic obstructive cardiomyopathy after septal myectomy. Ann. Thorac. Surg. 65, 1207–1214 (1998).
pubmed: 9594839
doi: 10.1016/S0003-4975(98)00187-8
Sun, D. et al. Posterior wall thickness associates with survival following septal myectomy for obstructive hypertrophic cardiomyopathy. JACC Heart Fail. 10, 831–837 (2022).
pubmed: 36328651
doi: 10.1016/j.jchf.2022.06.009
Woo, A. et al. Clinical and echocardiographic determinants of long-term survival after surgical myectomy in obstructive hypertrophic cardiomyopathy. Circulation 111, 2033–2041 (2005).
pubmed: 15824202
doi: 10.1161/01.CIR.0000162460.36735.71
Gigli, M. et al. Genetic risk of arrhythmic phenotypes in patients with dilated cardiomyopathy. J. Am. Coll. Cardiol. 74, 1480–1490 (2019).
pubmed: 31514951
pmcid: 6750731
doi: 10.1016/j.jacc.2019.06.072
De Frutos, F. et al. Natural history of MYH7-related dilated cardiomyopathy. J. Am. Coll. Cardiol. 80, 1447–1461 (2022).
pubmed: 36007715
doi: 10.1016/j.jacc.2022.07.023
Paldino, A. et al. Prognostic prediction of genotype vs phenotype in genetic cardiomyopathies. J. Am. Coll. Cardiol. 80, 1981–1994 (2022).
pubmed: 36396199
doi: 10.1016/j.jacc.2022.08.804
Ho, C. Y. et al. Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe). Circulation 138, 1387–1398 (2018).
pubmed: 30297972
pmcid: 6170149
doi: 10.1161/CIRCULATIONAHA.117.033200
Arends, M. et al. Characterization of classical and nonclassical fabry disease: a multicenter study. J. Am. Soc. Nephrol. 28, 1631–1641 (2017).
pubmed: 27979989
doi: 10.1681/ASN.2016090964
LaHaye, S., Lincoln, J. & Garg, V. Genetics of valvular heart disease. Curr. Cardiol. Rep. 16, 487 (2014).
pubmed: 24743897
pmcid: 4531840
doi: 10.1007/s11886-014-0487-2
Durst, R. et al. Mutations in DCHS1 cause mitral valve prolapse. Nature 525, 109–113 (2015).
pubmed: 26258302
pmcid: 4720389
doi: 10.1038/nature14670
Ta-Shma, A. et al. Congenital valvular defects associated with deleterious mutations in the PLD1 gene. J. Med. Genet. 54, 278–286 (2017).
pubmed: 27799408
doi: 10.1136/jmedgenet-2016-104259
Wünnemann, F. et al. Loss of ADAMTS19 causes progressive non-syndromic heart valve disease. Nat. Genet. 52, 40–47 (2020).
pubmed: 31844321
doi: 10.1038/s41588-019-0536-2
Hiemstra, Y. L. et al. Familial occurrence of mitral regurgitation in patients with mitral valve prolapse undergoing mitral valve surgery. Eur. J. Prev. Cardiol. 27, 272–280 (2020).
pubmed: 31475862
doi: 10.1177/2047487319874148
Lillo, R. et al. Echocardiography in Anderson–Fabry disease. Rev. Cardiovasc. Med. 23, 201 (2022).
doi: 10.31083/j.rcm2306201
Prasad, M. et al. Cardiorheumatology: cardiac involvement in systemic rheumatic disease. Nat. Rev. Cardiol. 12, 168–176 (2015).
pubmed: 25533796
doi: 10.1038/nrcardio.2014.206
Shammas, R. L. & Movahed, A. Sarcoidosis of the heart. Clin. Cardiol. 16, 462–472 (1993).
pubmed: 8358879
doi: 10.1002/clc.4960160603
Remenyi, B. et al. Valvular aspects of rheumatic heart disease. Lancet 387, 1335–1346 (2016).
pubmed: 27025439
doi: 10.1016/S0140-6736(16)00547-X
Desai, M. Y., Jellis, C. L., Kotecha, R., Johnston, D. R. & Griffin, B. P. Radiation-associated cardiac disease: a practical approach to diagnosis and management. JACC Cardiovasc. Imaging 11, 1132–1149 (2018).
pubmed: 30092970
doi: 10.1016/j.jcmg.2018.04.028
Freed, L. A. et al. Mitral valve prolapse in the general population: the benign nature of echocardiographic features in the Framingham Heart Study. J. Am. Coll. Cardiol. 40, 1298–1304 (2002).
pubmed: 12383578
doi: 10.1016/S0735-1097(02)02161-7
Van Wijngaarden, A. L., Kruithof, B. P. T., Vinella, T., Barge-Schaapveld, D. Q. C. M. & Ajmone Marsan, N. Characterization of degenerative mitral valve disease: differences between fibroelastic deficiency and Barlow’s disease. J. Cardiovasc. Dev. Dis. 8, 23 (2021).
pubmed: 33671724
pmcid: 7926852
Nascimento, R. et al. Is mitral valve prolapse a congenital or acquired disease? Am. J. Cardiol. 79, 226–227 (1997).
pubmed: 9193034
doi: 10.1016/S0002-9149(96)00722-9
Kruithof, B. P. T. et al. Stress-induced remodelling of the mitral valve: a model for leaflet thickening and superimposed tissue formation in mitral valve disease. Cardiovasc. Res. 5, 931–943 (2020).
Van Wijngaarden, A. L. et al. Identification of known and unknown genes associated with mitral valve prolapse using an exome slice methodology. J. Med. Genet. 57, 843–850 (2020).
pubmed: 32277046
doi: 10.1136/jmedgenet-2019-106715
Delwarde, C. et al. Genetics and pathophysiology of mitral valve prolapse. Front. Cardiovasc. Med. 10, 1077788 (2023).
pubmed: 36873395
pmcid: 9978496
doi: 10.3389/fcvm.2023.1077788
Gulotta, S. J., Gulco, L., Padmanabhan, V. & Miller, S. The syndrome of systolic click, murmur, and mitral valve prolapse — a cardiomyopathy? Circulation 49, 717–728 (1974).
pubmed: 4274147
doi: 10.1161/01.CIR.49.4.717
Yang, L. T. et al. Mitral valve prolapse patients with less than moderate mitral regurgitation exhibit early cardiac chamber remodeling. J. Am. Soc. Echocardiogr. 33, 815–825 (2020).
pubmed: 32222479
pmcid: 8193998
doi: 10.1016/j.echo.2020.01.016
Romero Daza, A. et al. Mitral valve prolapse morphofunctional features by cardiovascular magnetic resonance: more than just a valvular disease. J. Cardiovasc. Magn. Reson. 23, 107 (2021).
pubmed: 34629093
pmcid: 8504058
doi: 10.1186/s12968-021-00800-w
Kitkungvan, D. et al. Myocardial fibrosis in patients with primary mitral regurgitation with and without prolapse. J. Cardiovasc. Magn. Reson. 72, 823–834 (2018).
Han, Y. et al. Cardiovascular magnetic resonance characterization of mitral valve prolapse. JACC Cardiovasc. Imaging 1, 294–303 (2008).
pubmed: 19356441
doi: 10.1016/j.jcmg.2008.01.013
Bui, A. H. et al. Diffuse myocardial fibrosis in patients with mitral valve prolapse and ventricular arrhythmia. Heart 103, 204–209 (2017).
pubmed: 27515954
doi: 10.1136/heartjnl-2016-309303
Constant Dit Beaufils, A. L. et al. Replacement myocardial fibrosis in patients with mitral valve prolapse: relation to mitral regurgitation, ventricular remodeling, and arrhythmia. Circulation 143, 1763–1774 (2021).
pubmed: 33706538
doi: 10.1161/CIRCULATIONAHA.120.050214
Sabbag, A. et al. EHRA expert consensus statement on arrhythmic mitral valve prolapse and mitral annular disjunction complex in collaboration with the ESC Council on Valvular Heart Disease and the European Association of Cardiovascular Imaging endorsed by the Heart Rhythm Society, by the Asia Pacific Heart Rhythm Society, and by the Latin American Heart Rhythm Society. Europace 24, 1981–2003 (2022).
pubmed: 35951656
doi: 10.1093/europace/euac125
Perazzolo Marra, M. et al. Morphofunctional abnormalities of mitral annulus and arrhythmic mitral valve prolapse. Circ. Cardiovasc. Imaging 9, e005030 (2016).
pubmed: 27516479
pmcid: 4991345
doi: 10.1161/CIRCIMAGING.116.005030
Basso, C. et al. Arrhythmic mitral valve prolapse and sudden cardiac death. Circulation 132, 556–566 (2015).
pubmed: 26160859
doi: 10.1161/CIRCULATIONAHA.115.016291
Van Wijngaarden, A. L. et al. Parameters associated with ventricular arrhythmias in mitral valve prolapse with significant regurgitation. Heart 107, 411–418 (2021).
pubmed: 33004425
doi: 10.1136/heartjnl-2020-317451
Dejgaard, L. A. et al. The mitral annulus disjunction arrhythmic syndrome. J. Am. Coll. Cardiol. 72, 1600–1609 (2018).
pubmed: 30261961
doi: 10.1016/j.jacc.2018.07.070
Toh, H. et al. Prevalence and extent of mitral annular disjunction in structurally normal hearts: comprehensive 3D analysis using cardiac computed tomography. Eur. Heart J. Cardiovasc. Imaging 22, 614–622 (2021).
pubmed: 33713105
doi: 10.1093/ehjci/jeab022
Faletra, F. F. et al. Morphology of mitral annular disjunction in mitral valve prolapse. J. Am. Soc. Echocardiogr. 35, 176–186 (2022).
pubmed: 34508838
doi: 10.1016/j.echo.2021.09.002
Basso, C. et al. An echocardiographic survey of primary school children for bicuspid aortic valve. Am. J. Cardiol. 93, 661–663 (2004).
pubmed: 14996606
doi: 10.1016/j.amjcard.2003.11.031
Siu, S. C. & Silversides, C. K. Bicuspid aortic valve disease. J. Am. Coll. Cardiol. 55, 2789–2800 (2010).
pubmed: 20579534
doi: 10.1016/j.jacc.2009.12.068
Roberts, W. C. & Ko, J. M. Frequency by decades of unicuspid, bicuspid, and tricuspid aortic valves in adults having isolated aortic valve replacement for aortic stenosis, with or without associated aortic regurgitation. Circulation 111, 920–925 (2005).
pubmed: 15710758
doi: 10.1161/01.CIR.0000155623.48408.C5
Padang, R., Bagnall, R. D. & Semsarian, C. Genetic basis of familial valvular heart disease. Circ. Cardiovasc. Genet. 5, 569–580 (2012).
pubmed: 23074336
doi: 10.1161/CIRCGENETICS.112.962894
Glick, B. N. & Roberts, W. C. Congenitally bicuspid aortic valve in multiple family members. Am. J. Cardiol. 73, 400–404 (1994).
pubmed: 8109558
doi: 10.1016/0002-9149(94)90018-3
Martin, L. J. et al. Evidence in favor of linkage to human chromosomal regions 18q, 5q and 13q for bicuspid aortic valve and associated cardiovascular malformations. Hum. Genet. 121, 275–284 (2007).
pubmed: 17203300
doi: 10.1007/s00439-006-0316-9
Fedak, P. W. et al. Clinical and pathophysiological implications of a bicuspid aortic valve. Circulation 106, 900–904 (2002).
pubmed: 12186790
doi: 10.1161/01.CIR.0000027905.26586.E8
Yassine, N. M., Shahram, J. T. & Body, S. C. Pathogenic mechanisms of bicuspid aortic valve aortopathy. Front. Physiol. 8, 687 (2017).
pubmed: 28993736
pmcid: 5622294
doi: 10.3389/fphys.2017.00687
Owens, G. K., Kumar, M. S. & Wamhoff, B. R. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol. Rev. 84, 767–801 (2004).
pubmed: 15269336
doi: 10.1152/physrev.00041.2003
Feizi, O., Farrer Brown, G. & Emanuel, R. Familial study of hypertrophic cardiomyopathy and congenital aortic valve disease. Am. J. Cardiol. 41, 956–964 (1978).
pubmed: 565586
doi: 10.1016/0002-9149(78)90740-3
Brown, P. S. Jr, Roberts, C. S., McIntosh, C. L., Roberts, W. C. & Clark, R. E. Combined obstructive hypertrophic cardiomyopathy and stenotic congenitally bicuspid aortic valve. Am. J. Cardiol. 66, 1273–1275 (1990).
pubmed: 2239738
doi: 10.1016/0002-9149(90)91120-U
Agarwal, A. et al. Left ventricular noncompaction in patients with bicuspid aortic valve. J. Am. Soc. Echocardiogr. 26, 1306–1313 (2013).
pubmed: 24044978
doi: 10.1016/j.echo.2013.08.003
Jeong, H. et al. Prevalence, characteristics, and clinical significance of concomitant cardiomyopathies in subjects with bicuspid aortic valves. Yonsei Med. J. 60, 816–823 (2019).
pubmed: 31433579
pmcid: 6704018
doi: 10.3349/ymj.2019.60.9.816
Galat, A. et al. Aortic stenosis and transthyretin cardiac amyloidosis: the chicken or the egg? Eur. Heart J. 37, 3525–3531 (2016).
pubmed: 26908951
doi: 10.1093/eurheartj/ehw033
Tanskanen, M. et al. Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population based autopsy study. Ann. Med. 40, 232–239 (2008).
pubmed: 18382889
doi: 10.1080/07853890701842988
Osnabrugge, R. L. et al. Aortic stenosis in the elderly: disease prevalence and number of candidates for transcatheter aortic valve replacement: a meta-analysis and modeling study. J. Am. Coll. Cardiol. 62, 1002–1012 (2013).
pubmed: 23727214
doi: 10.1016/j.jacc.2013.05.015
Cooper, J. H. Localized dystrophic amyloidosis of heart valves. Hum. Pathol. 14, 649–653 (1983).
pubmed: 6190729
doi: 10.1016/S0046-8177(83)80208-1
Conte, M. et al. Isolated valve amyloidosis in aortic stenosis: a new clinical scenario? J. Am. Coll. Cardiol. 79, 3476 (2022).
doi: 10.1016/S0735-1097(22)04467-9
Kristen, A. V. et al. High prevalence of amyloid in 150 surgically removed heart valves — a comparison of histological and clinical data reveals a correlation to atheroinflammatory conditions. Cardiovasc. Pathol. 19, 228–235 (2010).
pubmed: 19502085
doi: 10.1016/j.carpath.2009.04.005
Fujimoto, T. et al. Case with transthyretin amyloid cardiomyopathy complicated with rapidly progressive aortic stenosis possibly caused by amyloid deposition in the aortic valve. Circ. Cardiovasc. Imaging 14, e013357 (2021).
pubmed: 34727706
doi: 10.1161/CIRCIMAGING.121.013357
Singal, A. K. et al. Concomitant transthyretin amyloidosis and severe aortic stenosis in elderly Indian population: a pilot study. JACC CardioOncol 3, 565–576 (2021).
pubmed: 34746852
pmcid: 8551518
doi: 10.1016/j.jaccao.2021.08.008
Merlini, G. & Bellotti, V. Molecular mechanisms of amyloidosis. N. Engl. J. Med. 349, 583–596 (2003).
pubmed: 12904524
doi: 10.1056/NEJMra023144
Henderson, B. C. et al. Oxidative remodeling in pressure overload induced chronic heart failure. Eur. J. Heart Fail. 9, 450–457 (2007).
pubmed: 17306621
doi: 10.1016/j.ejheart.2006.12.008
Park, J. Y. et al. Association of inflammation, myocardial fibrosis and cardiac remodelling in patients with mild aortic stenosis as assessed by biomarkers and echocardiography. Clin. Exp. Pharmacol. Physiol. 41, 185–191 (2014).
pubmed: 24471798
doi: 10.1111/1440-1681.12206
Rosenblum, H. et al. Unveiling outcomes in coexisting severe aortic stenosis and transthyretin cardiac amyloidosis. Eur. J. Heart Fail. 23, 250–258 (2021).
pubmed: 32729170
doi: 10.1002/ejhf.1974
Chacko, L. et al. Echocardiographic phenotype and prognosis in transthyretin cardiac amyloidosis. Eur. Heart J. 41, 1439–1447 (2020).
pubmed: 31950987
doi: 10.1093/eurheartj/ehz905
Ricci, F. et al. Prognostic significance of cardiac amyloidosis in patients with aortic stenosis: a systematic review and meta-analysis. JACC Cardiovasc. Imaging 14, 293–295 (2021).
pubmed: 32828772
doi: 10.1016/j.jcmg.2020.07.011
Myasoedova, V. A. et al. Red flags, prognostic impact, and management of patients with cardiac amyloidosis and aortic valve stenosis: a systematic review and meta-analysis. Front. Med. 9, 858281 (2022).
doi: 10.3389/fmed.2022.858281
Ternacle, J. et al. Aortic stenosis and cardiac amyloidosis: JACC review topic of the week. J. Am. Coll. Cardiol. 74, 2638–2651 (2019).
pubmed: 31753206
doi: 10.1016/j.jacc.2019.09.056
Dahl Pedersen, A. L. et al. Prevalence and prognostic implications of increased apical-to-basal strain ratio in patients with aortic stenosis undergoing transcatheter aortic valve replacement. J. Am. Soc. Echocardiogr. 33, 1465–1473 (2020).
pubmed: 32919852
doi: 10.1016/j.echo.2020.07.013
Cannata, F. et al. Transcatheter aortic valve replacement in aortic stenosis and cardiac amyloidosis: a systematic review and meta-analysis. ESC Heart Fail. 9, 3188–3197 (2022).
pubmed: 35770333
pmcid: 9715797
doi: 10.1002/ehf2.13876
Nitsche, C. et al. Prevalence and outcomes of concomitant aortic stenosis and cardiac amyloidosis. J. Am. Coll. Cardiol. 77, 128–139 (2021).
pubmed: 33181246
pmcid: 7805267
doi: 10.1016/j.jacc.2020.11.006
Scully, P. R. et al. Prevalence and outcome of dual aortic stenosis and cardiac amyloid pathology in patients referred for transcatheter aortic valve implantation. Eur. Heart J. 41, 2759–2767 (2020).
pubmed: 32267922
pmcid: 7395329
doi: 10.1093/eurheartj/ehaa170
Burzotta, F. et al. Clinical impact of heart team decisions for patients with complex valvular heart disease: a large, single-center experience. J. Am. Heart Assoc. 11, e024404 (2022).
pubmed: 35621200
pmcid: 9238748
doi: 10.1161/JAHA.121.024404
Ammar, K. A. et al. Cardiac amyloidosis presenting as severe mitral regurgitation. JACC Cardiovasc. Imaging 9, 1003–1006 (2016).
pubmed: 27344421
doi: 10.1016/j.jcmg.2016.03.011
Krishnaswamy, A., Hanna, M., Goodman, A. & Kapadia, S. R. First reported case of mitraclip placement due to mitral valve flail in the setting of cardiac amyloidosis. Circ. Heart Fail. 9, e003069 (2016).
pubmed: 27489249
doi: 10.1161/CIRCHEARTFAILURE.116.003069
Donà, C. et al. Unveiling cardiac amyloidosis, its characteristics, and outcomes among patients with MR undergoing transcatheter edge-to-edge MV repair. JACC Cardiovasc. Interv. 15, 1748–1758 (2022).
pubmed: 36008266
doi: 10.1016/j.jcin.2022.06.009
Braunlin, E. A. et al. Cardiac disease in patients with mucopolysaccharidosis: presentation, diagnosis and management. J. Inherit. Metab. Dis. 34, 1183–1197 (2011).
pubmed: 21744090
pmcid: 3228957
doi: 10.1007/s10545-011-9359-8
Rosser, B. A., Chan, C. & Hoschtitzky, A. Surgical management of valvular heart disease in mucopolysaccharidoses: a review of literature. Biomedicines 10, 375 (2022).
pubmed: 35203584
pmcid: 8962304
doi: 10.3390/biomedicines10020375
Mori, N. et al. Transcatheter aortic valve implantation for severe aortic stenosis in a patient with mucopolysaccharidosis type II (Hunter syndrome) accompanied by severe airway obstruction. J. Cardiol. Cases 25, 49–51 (2021).
pubmed: 35024070
pmcid: 8721259
doi: 10.1016/j.jccase.2021.06.008
Lillo, R., Ingrasciotta, G., Locorotondo, G., Lombardo, A. & Graziani, F. An unusual case of mitral valve chordal rupture. Echocardiography 38, 2109–2111 (2021).
pubmed: 34713487
doi: 10.1111/echo.15228
Calcagni, G. et al. Cardiac defects, morbidity and mortality in patients affected by RASopathies. CARNET study results. Int. J. Cardiol. 245, 92–98 (2017).
pubmed: 28768581
doi: 10.1016/j.ijcard.2017.07.068
Sade, L. E. & Akdogan, A. Imaging for screening cardiovascular involvement in patients with systemic rheumatologic diseases: more questions than answers. Eur. Heart J. Cardiovasc. Imaging 20, 967–978 (2019).
pubmed: 31230066
doi: 10.1093/ehjci/jez171
Donnellan, E. et al. Outcomes of patients with mediastinal radiation-associated severe aortic stenosis undergoing transcatheter aortic valve replacement. Circulation 138, 1752–1754 (2018).
pubmed: 30354469
doi: 10.1161/CIRCULATIONAHA.118.035514
Donnellan, E. et al. Longterm outcomes of patients with mediastinal radiation-associated severe aortic stenosis and subsequent surgical aortic valve replacement: a matched cohort study. J. Am. Heart Assoc. 6, e005396 (2017).
pubmed: 28476874
pmcid: 5524090
doi: 10.1161/JAHA.116.005396
Donnellan, E. et al. Outcomes of patients with mediastinal radiation-associated mitral valve disease undergoing cardiac surgery. Circulation 140, 1288–1290 (2019).
pubmed: 31589484
doi: 10.1161/CIRCULATIONAHA.119.040546
Wilde, A. A. M. et al. Expert consensus statement on the state of genetic testing for cardiac diseases. Europace 24, 1307–1367 (2022).
pubmed: 35373836
pmcid: 9435643
doi: 10.1093/europace/euac030
Rapezzi, C. et al. Diagnostic work-up in cardiomyopathies: bridging the gap between clinical phenotypes and final diagnosis. A position statement from the ESC working group on myocardial and pericardial diseases. Eur. Heart J. 34, 1448–1458 (2013).
pubmed: 23211230
doi: 10.1093/eurheartj/ehs397